SG11201900486WA - Treatment and prevention of sleep disorders - Google Patents
Treatment and prevention of sleep disordersInfo
- Publication number
- SG11201900486WA SG11201900486WA SG11201900486WA SG11201900486WA SG11201900486WA SG 11201900486W A SG11201900486W A SG 11201900486WA SG 11201900486W A SG11201900486W A SG 11201900486WA SG 11201900486W A SG11201900486W A SG 11201900486WA SG 11201900486W A SG11201900486W A SG 11201900486WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- night
- july
- pct
- treatment
- Prior art date
Links
- 208000019116 sleep disease Diseases 0.000 title abstract 4
- 230000002265 prevention Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 208000020685 sleep-wake disease Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 abstract 1
- 239000000902 placebo Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662366960P | 2016-07-26 | 2016-07-26 | |
| US201762536097P | 2017-07-24 | 2017-07-24 | |
| PCT/IB2017/054506 WO2018020418A1 (en) | 2016-07-26 | 2017-07-25 | Treatment and prevention of sleep disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900486WA true SG11201900486WA (en) | 2019-02-27 |
Family
ID=59714072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900486WA SG11201900486WA (en) | 2016-07-26 | 2017-07-25 | Treatment and prevention of sleep disorders |
Country Status (20)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190008A1 (ar) | 2016-07-26 | 2019-01-24 | Purdue Pharma Lp | علاج ومنع اضطرابات النوم |
| CN111601591A (zh) * | 2018-01-24 | 2020-08-28 | 普渡制药公司 | 睡眠障碍的治疗和预防 |
| CA3097445A1 (en) * | 2018-04-16 | 2019-10-24 | Technologies Hop-Child, Inc. | Systems and methods for the determination of arousal states, calibrated communication signals and monitoring arousal states |
| KR102198846B1 (ko) * | 2018-06-29 | 2021-01-05 | 다인기술 주식회사 | 배뇨에 관한 설문을 수행하는 방법, 시스템 및 비일시성의 컴퓨터 판독 가능 기록 매체 |
| CN111359074B (zh) * | 2018-12-26 | 2022-08-02 | 财团法人工业技术研究院 | 个人化参数学习方法、睡眠辅助装置及存储介质 |
| US11547350B2 (en) * | 2018-12-26 | 2023-01-10 | Industrial Technology Research Institute | Personalized parameter learning method, sleep-aid device and non-transitory computer readable medium |
| JP7709916B2 (ja) * | 2019-01-31 | 2025-07-17 | パーデュー ファーマ エルピー | 置換キノキサリン型架橋ピペリジン化合物の多形形態 |
| KR20220062361A (ko) * | 2019-09-13 | 2022-05-16 | 다케다 야쿠힌 고교 가부시키가이샤 | 과도한 졸림의 치료를 위한 오렉신 2 수용체 효능제의 용도 |
| CN114159568B (zh) * | 2020-09-11 | 2025-08-01 | 北京原基华毅生物科技有限公司 | Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用 |
| CA3219412A1 (en) * | 2021-05-21 | 2022-11-24 | Garth WHITESIDE | Methods of treating interstitial cystitis/bladder pain syndrome |
| TWI804037B (zh) * | 2021-11-02 | 2023-06-01 | 長庚醫療財團法人高雄長庚紀念醫院 | 生酮飲食之評估系統及其運作方法 |
| WO2025085818A1 (en) | 2023-10-19 | 2025-04-24 | Purdue Pharma L.P. | Sunobinop for use in method of treating alcohol use disorder |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| ATE301457T1 (de) | 1995-06-12 | 2005-08-15 | Searle & Co | Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor |
| US6572891B1 (en) | 1999-10-23 | 2003-06-03 | Alkaloid Ad | Sublingual oral dosage form |
| ES2392340T3 (es) | 2002-03-29 | 2012-12-07 | Mitsubishi Tanabe Pharma Corporation | Remedio para los trastornos del sueño |
| AU2004238321B2 (en) | 2003-05-07 | 2009-08-27 | Samyang Biopharmaceuticals Corporation | Highly plastic granules for making fast melting tablets |
| AR045939A1 (es) | 2003-09-25 | 2005-11-16 | Solvay Pharm Bv | Derivados de bencimidazolona y quinazolinona como agonistas de los receptores orl 1 humanos |
| US7355045B2 (en) | 2004-01-05 | 2008-04-08 | Applera Corporation | Isotopically enriched N-substituted piperazine acetic acids and methods for the preparation thereof |
| WO2006025267A1 (ja) * | 2004-08-31 | 2006-03-09 | Mitsubishi Pharma Corporation | Per2タンパク質レベルの低下を作用機序とする睡眠障害治療薬 |
| US9308175B2 (en) | 2006-09-15 | 2016-04-12 | Echo Pharmaceuticals B.V. | Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances |
| ES2534546T3 (es) | 2007-08-31 | 2015-04-24 | Purdue Pharma Lp | Compuestos de piperidina, de tipo quinoxalina sustituida, y usos de los mismos |
| NZ588407A (en) | 2008-03-11 | 2012-07-27 | Takeda Pharmaceutical | Orally-disintegrating solid preparation |
| RS52590B2 (sr) * | 2008-07-21 | 2018-05-31 | Purdue Pharma Lp | Jedinjenja tipa supstituisanog hinoksalina sa premošćenim piperidinom i njihova upotreba |
| EP2797912B1 (en) | 2011-12-01 | 2016-05-25 | Purdue Pharma L.P. | Azetidine-substituted quinoxaline-type piperidine compounds and uses thereof |
| US9040533B2 (en) * | 2012-12-27 | 2015-05-26 | Purdue Pharma L.P. | Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators |
| US10118927B2 (en) * | 2012-12-27 | 2018-11-06 | Purdue Pharma L.P. | Substituted piperidin-4-amino-type compounds and uses thereof |
| JOP20190008A1 (ar) | 2016-07-26 | 2019-01-24 | Purdue Pharma Lp | علاج ومنع اضطرابات النوم |
-
2017
- 2017-06-16 JO JOP/2019/0008A patent/JOP20190008A1/ar unknown
- 2017-07-25 US US16/318,686 patent/US10974081B2/en active Active
- 2017-07-25 KR KR1020217002556A patent/KR102531366B1/ko active Active
- 2017-07-25 NZ NZ750817A patent/NZ750817A/en unknown
- 2017-07-25 JP JP2019503994A patent/JP7198197B2/ja active Active
- 2017-07-25 CN CN201780046414.XA patent/CN109689058B/zh active Active
- 2017-07-25 TW TW106124940A patent/TWI661827B/zh active
- 2017-07-25 WO PCT/IB2017/054506 patent/WO2018020418A1/en unknown
- 2017-07-25 MX MX2019001036A patent/MX388469B/es unknown
- 2017-07-25 BR BR112019001457-8A patent/BR112019001457A2/pt not_active Application Discontinuation
- 2017-07-25 SG SG11201900486WA patent/SG11201900486WA/en unknown
- 2017-07-25 TN TNP/2019/000019A patent/TN2019000019A1/en unknown
- 2017-07-25 CA CA3031388A patent/CA3031388C/en active Active
- 2017-07-25 AU AU2017304898A patent/AU2017304898B2/en active Active
- 2017-07-25 KR KR1020197004527A patent/KR102210209B1/ko active Active
- 2017-07-25 EP EP17758282.2A patent/EP3490563A1/en active Pending
-
2019
- 2019-01-17 IL IL264294A patent/IL264294B/en unknown
- 2019-01-25 CL CL2019000190A patent/CL2019000190A1/es unknown
- 2019-01-25 PH PH12019500177A patent/PH12019500177A1/en unknown
- 2019-02-19 ZA ZA2019/01055A patent/ZA201901055B/en unknown
- 2019-02-26 EC ECSENADI201914247A patent/ECSP19014247A/es unknown
-
2020
- 2020-11-19 AU AU2020273332A patent/AU2020273332B2/en active Active
-
2021
- 2021-03-08 US US17/195,434 patent/US11738023B2/en active Active
- 2021-04-21 JP JP2021072166A patent/JP7291172B2/ja active Active
-
2023
- 2023-06-28 US US18/343,182 patent/US12370191B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900486WA (en) | Treatment and prevention of sleep disorders | |
| SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201900361RA (en) | Methods of treating prostate cancer | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
| SG11201805385QA (en) | Bromodomain and extra-terminal protein inhibitor combination therapy | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201804220SA (en) | Activated stem cells and systemic treatment methods for infected wounds | |
| SG11201809708PA (en) | Physiologically balanced injectable formulations of fosnetupitant |